Study on the effects of statin use in immunotherapy for elderly cancer patients on immune-related adverse reactions and quality of life
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Objective: To assess the effects of statins on immune-related adverse reactions, quality of life, and clinical outcomes in older adults receiving cancer immunotherapy.Methods: We retrospectively enrolled 150 elderly cancer patients admitted to Beijing Shunyi Hospital between August 2023 and March 2025, who were categorized into a study group (n=94) and a control group (n=56) depending on their use of oral statins.Clinical efficacy, laboratory parameters, quality of life, and adverse reactions were compared between groups.Patients on statins with biomarker elevations ≤2.5 times the upper limit of normal (ULN) (n=78) were further divided into discontinuation (n=35) and continuation (n=43) subgroups to compare biomarker normalization rates.Progression-free survival (PFS) was assessed, and Cox regression analyses were performed to identify PFS-associated factors.Results: No significant differences were observed in general characteristics, clinical efficacy, or most laboratory indicators between the two groups (all P>0.05).Following treatment, the study group demonstrated more pronounced improvements in inflammatory/tumor markers and lipid profiles (all P0.05).Conclusion: In elderly cancer patients receiving immunotherapy, concomitant statin use did not increase adverse reactions, may improve quality of life, and did not compromise clinical efficacy.The observed PFS benefit was modest.Statins should be considered as an adjunctive therapy, with decisions individualized based on lipid profile and cardiovascular risk.
Fields of Study & Subjects
Cancer
Lipids
and Metabolism
Cancer Immunotherapy and Biomarkers
Lipoproteins and Cardiovascular Health
Publication details
- Journal / source
- American Journal of Cancer Research
- Volume
- 16
- Issue
- 3
- Pages
- 825–839
- Publication date
- 1 January 2026
- Language
- EN